GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

romosozumab   Click here for help

GtoPdb Ligand ID: 8092

Synonyms: AMG-785 | CDP-7851 | Evenity® | romosozumab-aqqg
Approved drug
romosozumab is an approved drug (Japan, FDA and EMA (2019))
Compound class: Antibody
Comment: Romosozumab is a humanised anti-sclerostin monoclonal antibody that was developed by Amgen and UCB for the treatment of osteoporosis [4-5]. Amgen holds patent protection claiming the polypeptide composition of romosozumab in the US and the EU (expected expiry in 2026).
Classification Click here for help
Compound class Antibody
Approved drug? Yes. Japan PMDA (2019)  |  EU EMA (2019)  |  US FDA (2019)
International Nonproprietary Names Click here for help
INN number INN
9533 romosozumab
Synonyms Click here for help
AMG-785 | CDP-7851 | Evenity® | romosozumab-aqqg
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 404
Other databases
GtoPdb PubChem SID 249565772
Search PubMed clinical trials romosozumab
Search PubMed titles romosozumab
Search PubMed titles/abstracts romosozumab
Wikipedia Romosozumab